Skip to content

Main Navigation

Vor Bio
  • News & Media
  • Publications
  • Join Us
  • Contact
  • Blog
  • Search
  • About Us
    • Overview
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • Overview
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Overview
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Overview
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Overview
    • Our Investigational Program
    • Clinical Trials
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts

Publication Programs: Platform

Cell & Gene – White Paper

Leveraging Human Genetics To Advance Cell Therapies For Treatment Of Blood Cancers […]

Read More… from Cell & Gene – White Paper

Rocky Conference – 2022 – Poster Presentation 71

A machine learning approach incorporating germline information improves genotyping of CRISPR-Cas9 gene editing events at single cell resolution […]

Read More… from Rocky Conference – 2022 – Poster Presentation 71

ASH – 2022 – Poster Presentation 4587

Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment […]

Read More… from ASH – 2022 – Poster Presentation 4587

SITC – 2022 – Poster Presentation P334

Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia […]

Read More… from SITC – 2022 – Poster Presentation P334

ESGCT – 2022 – Poster Presentation P432

Multiplex deletion of myeloid antigens by base editing in human hematopoietic stem and progenitor cells (HSPCs) enables potential for next generation transplant for acute myeloid leukemia (AML) treatment […]

Read More… from ESGCT – 2022 – Poster Presentation P432

ESGCT – 2022 – Poster Presentation P150

Efficient knockout of both CD33 and CLL-1 by multiplex genome editing of human hematopoietic stem cells enhances the potential of next- generation transplants for acute myeloid leukemia (AML) treatment […]

Read More… from ESGCT – 2022 – Poster Presentation P150

Bioprocess International – 2022 – Poster Presentation CT11

Automated Closed Cell Processing System De-Risks Gene-Edited CD34+ Hematopoietic Stem Cell Manufacturing […]

Read More… from Bioprocess International – 2022 – Poster Presentation CT11

ISMB – 2022 – Poster Presentation 859

TransACT enhances detection and characterization of translocation events from high-throughput sequencing data at base-pair resolution for gene editing products […]

Read More… from ISMB – 2022 – Poster Presentation 859

EHA – 2022 – Poster Presentation 1429

Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment […]

Read More… from EHA – 2022 – Poster Presentation 1429

Posts navigation

  • 1
  • 2
  • 3
  • »

Share This Post

Recent Posts

  • A Conversation with a First-Generation Woman in STEM: International Day of Women & Girls in Science February 10, 2023
  • How our unwavering focus on patients helped us weather a tough 2022 for biotech December 28, 2022
  • My journey giving a gift of hope by donating bone marrow December 20, 2022
  • This Thanksgiving and every day, take stock of everything you are grateful for November 23, 2022
  • Teamwork on full display during our clinical manufacturing facility buildout November 9, 2022
  • Lending a Hand, Stepping Up for the Larger Community October 4, 2022
  • Cultivating Company Culture: The Process Behind Vor Bio’s Core Values September 13, 2022
  • The Online Reflection of Vor Bio August 2, 2022
Logo Vor Biopharma White

Follow us on social media:

Twitter LinkedIn
  • About Us
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Our Investigational Program
    • Clinical Trials
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts
  • News & Media
  • Publications
  • Join Us
  • Blog

© 2023 Vor Biopharma

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.